These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7857586)

  • 41. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Involvement of dopaminergic receptor subtypes in straub tail behaviour in mice.
    Zarrindast MR; Bayat A; Shafaghi B
    Gen Pharmacol; 1993 Jan; 24(1):127-30. PubMed ID: 8097737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.
    da Silva Alves F; Bakker G; Schmitz N; Abeling N; Hasler G; van der Meer J; Nederveen A; de Haan L; Linszen D; van Amelsvoort T
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1577-86. PubMed ID: 23978392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The dopamine hypothesis of schizophrenia revisited.
    van Kammen DP
    Psychoneuroendocrinology; 1979 Jan; 4(1):37-46. PubMed ID: 39306
    [No Abstract]   [Full Text] [Related]  

  • 46. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
    Hunt JI; Singh H; Simpson GM
    J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D; Labarca R; Linnoila M; Roy A; Hommer D; Everett D; Paul SM
    Science; 1984 Aug; 225(4665):954-7. PubMed ID: 6474162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment.
    Schröder J; Silvestri S; Bubeck B; Karr M; Demisch S; Scherrer S; Geider FJ; Sauer H
    Biol Psychiatry; 1998 May; 43(9):660-5. PubMed ID: 9582999
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Remoxipride in schizophrenia. A preliminary report.
    den Boer JA; Verhoeven WM; Westenberg HG
    Acta Psychiatr Scand; 1986 Oct; 74(4):409-14. PubMed ID: 2880457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
    Breier A; Davis OR; Buchanan RW; Moricle LA; Munson RC
    Arch Gen Psychiatry; 1993 Jul; 50(7):541-50. PubMed ID: 8317948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipsychotic treatment with alpha-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools.
    Larsson M; Ohman R; Wallin L; Wålinder J; Carlsson A
    J Neural Transm; 1984; 60(2):115-32. PubMed ID: 6149256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Psychopharmacologic approaches to schizophrenic psychoses].
    Giacardy-Paty M; Soubrouillard C; Blin O
    Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Major psychosis and dopamine: controversial features and some suggestions.
    Miller R
    Psychol Med; 1984 Nov; 14(4):779-89. PubMed ID: 6152742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
    Amin F; Davidson M; Kahn RS; Schmeidler J; Stern R; Knott PJ; Apter S
    Schizophr Bull; 1995; 21(1):53-66. PubMed ID: 7770741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
    White FJ; Bednarz LM; Wachtel SR; Hjorth S; Brooderson RJ
    Pharmacol Biochem Behav; 1988 May; 30(1):189-93. PubMed ID: 2902644
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An un-dopamine hypothesis of schizophrenia.
    Alpert M; Friedhoff AJ
    Schizophr Bull; 1980; 6(3):387-9. PubMed ID: 6105705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The concept of supersensitivity psychosis.
    Kirkpatrick B; Alphs L; Buchanan RW
    J Nerv Ment Dis; 1992 Apr; 180(4):265-70. PubMed ID: 1348269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation of dopaminergic terminal excitability by D1 selective agents: further characterization.
    Diana M; Young SJ; Groves PM
    Neuroscience; 1991; 42(2):441-9. PubMed ID: 1680226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.